Q3FY24 results and release. Subdued.
Jubilant Ingrevia has recently inaugurated an innovative facility for Diketene Derivatives in Gajraula, Uttar Pradesh. This plant will significantly enhance the company’s production capacity by adding 2,000 tonnes per annum (tpa) for manufacturing high-value esters.
The expansion into diketene derivatives represents a strategic move by the company to tap into new markets, particularly in the US and EU regions. These derivatives are poised for substantial growth, positioning them as a key segment within the company’s specialty chemicals portfolio.
With this facility,the organisation is not only bolstering its existing offerings but also signalling a shift in strategy towards capturing emerging opportunities in downstream derivatives. The company is committed to further strengthening its presence in this segment, with plans to introduce new derivatives in addition to the existing ones.
This forward-looking approach aligns with the corporation’s long-term strategic objectives, as it aims to build an advanced product portfolio and solidify its position as a leader in the diketene derivatives market. With innovation and expansion at the forefront, the company is poised to capitalise on evolving market trends and deliver value to its customers worldwide.
7 Likes
kindly give the Report details
Jubilant Ingrevia’s subsidiary has signed a prolific deal (USD 300 Million plus over the next few years) with an International Company. Following is the notification submitted to exchanges
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Jubilant Agro Sciences Limited (‘JASL’), wholly owned subsidiary of the Company, has entered into an agreement with a leading Agrochemical Company (‘Customer’) to produce an Agro Intermediate for one of the key Agro actives of the Customer.
Not sure how profitable this deal is but feels like a significant one.
One thing I find confusing is that the notification (https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7e9793cb-4792-4d13-a0e7-ac792c2676af.pdf) mentions that the revenue is USD 500 Million; the company name was unclear. So I looked at the financial statement of Jubilant Agro Science Ltd. I found following info
Clearly JASL hardly had significant business in 2023-24. And so this deal seems to be really big one for JASL (and so for Jubilant Ingrevia).
Thanks,
Krishna
5 Likes
Today the stock has crossed the highest price (last seen in October 2021) post listing.
Other than recent CDMO orders, anything major which is happening behind the scene - and unknown to retail investors.
Disc: Invested
4 Likes
RETAIL holding has been continuously going down. the no. of shareholders and retail holding as well. and smart money has been moving in.
disc. invested recently
2 Likes
Jubilant Infrastructure Limited (“JIL”), wholly owned subsidiary of the
Company at its Board Meeting held today has approved purchasing of 6.67% equity Share in
Forum I Aviation Private Limited (‘FAPL’) from Hero Fincorp Limited & Mr. Sunil Kant
Munjal.
JIL already have couple of verticals to focus but don’t know why they are increasing stack in tricky and OOB vertical. Ultimately market will discount this if this starts pulling out revenue in some or other way.!
Disc : tracking for personal reasons. Not invested!
1 Like
Jubilant Ingrevia | Outlook
We expect continued growth in Q4 FY25, driven by Specialty Chemicals and Nutrition & Health Solutions, cost management, new plant operations, and improved efficiency.
2 Likes